Trial Profile
Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enrolled in the Neurocognitive Function Trial
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 30 Sep 2020 This trial has been completed in Bulgaria, according to European Clinical Trials Database record.
- 15 May 2020 Status changed from active, no longer recruiting to discontinued.
- 05 Feb 2020 Status changed from recruiting to active, no longer recruiting.